Affimed N.V. (NASDAQ:AFMD) shares are trading higher on Monday. On Saturday, the company announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the ongoing AFM24-102 study in non-small cell lung cancer (NSCLC). As of the updated data cutoff on May 13, for the 17 EGFRwt patients previously reported, 15 patients were response-evaluable. Four confirmed objective responses were seen: 1 complete response (CR) and three partial responses (PR). In addition, eight patients achieved stable disease (SD), resulting in a disease control rate …